Recombinant Neosartorya fumigata Solute carrier family 25 member 38 homolog (AFUB_069300)

What is Neosartorya fumigata Solute Carrier Family 25 Member 38 Homolog?

Neosartorya fumigata Solute carrier family 25 member 38 homolog (AFUB_069300) is a mitochondrial membrane protein characterized as a glycine transporter . The protein consists of 320 amino acids and belongs to the solute carrier family 25, a group of proteins responsible for transporting various molecules across mitochondrial membranes. The protein has UniProt ID B0Y4J4 and is encoded by the AFUB_069300 gene in Neosartorya fumigata (also known as Aspergillus fumigatus) . As a mitochondrial carrier protein, it likely plays an essential role in fungal metabolism, particularly in glycine transport into mitochondria, which is crucial for various metabolic pathways.

How is the recombinant protein produced and prepared for research use?

The recombinant full-length Neosartorya fumigata Solute carrier family 25 member 38 homolog protein is typically produced using E. coli expression systems with an N-terminal His-tag for purification purposes . The expression process involves:

• Cloning the full coding sequence (amino acids 1-320) into a suitable expression vector

• Transforming the construct into E. coli expression host cells

• Inducing protein expression under optimized conditions

• Cell lysis and protein extraction

• Purification via His-tag affinity chromatography

• Lyophilization to create a stable powder form

For research applications, the lyophilized protein is reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL, with addition of 5-50% glycerol (typically 50%) as a cryoprotectant for long-term storage at -20°C/-80°C . Repeated freeze-thaw cycles should be avoided to maintain protein integrity and functionality.

How can I assess the functional activity of recombinant AFUB_069300 protein?

Assessing the functional activity of the recombinant Neosartorya fumigata Solute carrier family 25 member 38 homolog requires specialized transport assays since it functions as a mitochondrial glycine transporter. A methodological approach includes:

• Liposome reconstitution assay:

  • Purify the recombinant protein to >95% homogeneity using additional chromatography steps beyond initial His-tag purification

  • Reconstitute the protein into liposomes containing appropriate phospholipids

  • Load liposomes with internal substrate or buffer

  • Measure glycine transport by monitoring substrate accumulation inside liposomes over time

• Cell-based transport assays:

  • Express the protein in transport-deficient cell lines

  • Measure glycine uptake using radiolabeled glycine or fluorescent glycine analogs

  • Compare transport rates with and without specific inhibitors

• Biophysical characterization:

  • Analyze protein stability and folding using circular dichroism

  • Assess substrate binding using isothermal titration calorimetry or microscale thermophoresis

These functional assays should include appropriate positive and negative controls, and researchers should be aware that the His-tag may influence transport activity, potentially necessitating tag removal for certain applications.

What structural features define the Solute Carrier Family 25 transporters, and how might they apply to AFUB_069300?

Solute Carrier Family 25 (SLC25) transporters share several structural characteristics that likely apply to AFUB_069300:

To experimentally validate these structural features in AFUB_069300:

• Perform computational structure prediction using homology modeling based on known SLC25 family structures

• Apply site-directed mutagenesis to confirm the importance of predicted key residues

• Attempt crystallization or cryo-EM studies to determine the three-dimensional structure

• Use molecular dynamics simulations to predict substrate binding and transport mechanisms

The glycine transport function suggests this protein may share structural similarities with other mitochondrial amino acid transporters within the SLC25 family.

How does the fungal AFUB_069300 differ from mammalian SLC25 family transporters?

Understanding the differences between fungal AFUB_069300 and mammalian SLC25 transporters is crucial for potential therapeutic targeting:

To experimentally characterize these differences:

• Perform detailed sequence and structural alignments between AFUB_069300 and human SLC25 family members

• Compare transport kinetics (Km, Vmax) for various substrates

• Conduct inhibitor screening to identify compounds that selectively target the fungal transporter

• Analyze the protein interactome in fungal vs. mammalian systems

These differences could potentially be exploited for developing antifungal therapies that selectively target the fungal transporter without affecting human homologs.

What are the optimal storage and handling conditions for maintaining protein activity?

Proper storage and handling of recombinant Neosartorya fumigata Solute carrier family 25 member 38 homolog is critical for maintaining its structural integrity and functional activity:

For optimal handling:

• Centrifuge vials briefly before opening to collect contents at the bottom

• Prepare smaller working aliquots immediately after reconstitution

• Use low-protein-binding tubes for storage

• Monitor protein stability with routine activity assays after storage

• Consider adding protease inhibitors for sensitive applications

These storage and handling protocols are essential to ensure experimental reproducibility and reliable results in downstream applications.

What experimental controls should be included when using this protein in research?

When working with recombinant Neosartorya fumigata Solute carrier family 25 member 38 homolog, incorporating appropriate experimental controls is essential:

Additionally, researchers should include:

• Concentration-dependent controls (dose-response)

• Time-course experiments to establish kinetics

• Inhibitor controls to confirm mechanism of action

• Expression verification through Western blotting before functional studies

• Batch-to-batch consistency controls when using multiple protein preparations

These controls help distinguish specific protein effects from artifacts and ensure experimental rigor and reproducibility.

How can this protein be used in studying fungal metabolism and potential antifungal targets?

The recombinant Neosartorya fumigata Solute carrier family 25 member 38 homolog offers several methodological approaches for investigating fungal metabolism and identifying potential antifungal targets:

• Metabolic flux analysis:

  • Incorporate isotope-labeled glycine in fungal cultures

  • Monitor metabolite distributions with and without AFUB_069300 inhibition

  • Quantify changes in downstream metabolic pathways

• Genetic manipulation studies:

  • Create knockout or knockdown strains of AFUB_069300 in Neosartorya fumigata

  • Assess phenotypic changes in growth, morphology, and virulence

  • Complement with recombinant protein to confirm specificity

• Drug discovery applications:

  • Develop high-throughput screening assays using the recombinant protein

  • Screen compound libraries for selective inhibitors

  • Validate hits in fungal growth and infection models

• Structure-based drug design:

  • Use the recombinant protein for structural studies (X-ray crystallography, cryo-EM)

  • Employ in silico docking to identify potential binding pockets

  • Design rational inhibitors based on structural information

• Pathogenesis studies:

  • Examine the role of AFUB_069300 in host-pathogen interactions

  • Investigate its expression during different infection stages

  • Assess its contribution to fungal survival in various host environments

Given the importance of Aspergillus fumigatus as a major pathogen causing invasive aspergillosis with 80-90% mortality rates in leukemia patients , targeting metabolic transporters like AFUB_069300 could represent a novel therapeutic approach, especially as this pathway may be essential for fungal survival within the host.

What are common challenges in working with recombinant membrane proteins like AFUB_069300?

Membrane proteins present unique challenges in recombinant expression and handling:

When troubleshooting:

• Verify protein integrity by SDS-PAGE and Western blotting before functional studies

• Assess protein homogeneity through dynamic light scattering

• Monitor secondary structure using circular dichroism to confirm proper folding

• Test multiple reconstitution protocols to identify optimal conditions

• Consider nanodiscs or other membrane mimetics for stabilization

These approaches can help overcome the inherent difficulties in working with recombinant membrane transporters like AFUB_069300.

How can I verify the authenticity and purity of the recombinant protein?

Verification of recombinant Neosartorya fumigata Solute carrier family 25 member 38 homolog authenticity and purity requires multiple analytical techniques:

• SDS-PAGE analysis:

  • Expected molecular weight: ~34-36 kDa (including His-tag)

  • Should show >90% purity with minimal degradation products

  • Silver staining for detecting low-abundance contaminants

• Western blotting:

  • Primary detection using anti-His antibody

  • Secondary confirmation with specific antibodies against AFUB_069300 (if available)

  • Verify expected migration pattern and absence of truncated forms

• Mass spectrometry:

  • Peptide mass fingerprinting to confirm identity

  • LC-MS/MS for sequence confirmation and post-translational modification analysis

  • Intact protein mass to verify full-length expression

• Functional verification:

  • Transport activity assays using proteoliposomes

  • Binding studies with known substrates or inhibitors

  • Comparison with predicted activity based on sequence homology

• Biophysical characterization:

  • Circular dichroism to verify secondary structure elements

  • Dynamic light scattering to assess homogeneity and aggregation state

  • Thermal shift assays to evaluate protein stability

Researchers should aim for >95% purity for most applications, with >98% recommended for structural studies and detailed biochemical characterization.

How can computational approaches enhance research on AFUB_069300?

Computational methods offer powerful tools for studying Neosartorya fumigata Solute carrier family 25 member 38 homolog:

A methodological workflow might include:

• Multiple sequence alignment of AFUB_069300 with characterized SLC25 family members

• Construction of homology models using AlphaFold2 or similar tools

• Refinement of models through molecular dynamics simulations in a lipid bilayer

• Identification of potential substrate binding sites and gating residues

• Virtual screening campaigns to identify potential selective inhibitors

• Experimental validation of computational predictions

These computational approaches can guide experimental design, help interpret results, and accelerate discovery of inhibitors that might serve as leads for antifungal development.

What insights can AFUB_069300 provide about fungal pathogenesis and host-pathogen interactions?

Investigating AFUB_069300 can yield valuable insights into Neosartorya fumigata pathogenesis:

• Metabolic adaptation during infection:

  • AFUB_069300 likely facilitates glycine transport, which may be crucial during certain infection stages

  • Comparison of expression levels between saprophytic growth and invasive infection

  • Analysis of metabolic rewiring during adaptation to host environment

• Potential role in virulence:

  • Creation of knockout strains to assess virulence in animal models

  • Evaluation of growth and survival under various stress conditions

  • Examination of biofilm formation capacity with and without functional AFUB_069300

• Host immune recognition:

  • Assessment of AFUB_069300 as a potential antigen recognized by host immune system

  • Investigation of antibody responses in patients with different forms of aspergillosis

  • Determination of T-cell epitopes within the protein sequence

• Therapeutic targeting:

  • Exploitation of structural differences from human homologs for selective inhibition

  • Development of antibodies or small molecules targeting AFUB_069300

  • Evaluation of combination approaches with existing antifungals

Given that invasive aspergillosis has a mortality rate of 80-90% even with treatment and occurs in 10-25% of all leukemia patients , understanding the role of metabolic transporters like AFUB_069300 could provide crucial insights into fungal adaptation mechanisms during infection and potentially reveal new therapeutic approaches.